Evidence map›Paper›PMID 29472587›Full record

ArticleThe pharmacogenomics journal2019

Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.

K Tryfonidis, C Papadaki, S Assele, E Lagoudaki, J Menis, A Koutsopoulos, M Trypaki, E Tsakalaki, M Sfakianaki, B Hasan and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

K TryfonidisEORTC, Headquarters, Brussels, Belgium. konstantinos.tryfonidis@gmail.com.
C PapadakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
S AsseleEORTC, Headquarters, Brussels, Belgium.
E LagoudakiDepartment of Pathology, University of Crete, Heraklion, Greece.
J MenisInstitute Gustave Roussy, Paris, France.
A KoutsopoulosDepartment of Pathology, University of Crete, Heraklion, Greece.ORCID http://orcid.org/0000-0002-8430-7565
M TrypakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
E TsakalakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
M SfakianakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
B HasanEORTC, Headquarters, Brussels, Belgium.
E StathopoulosDepartment of Pathology, University of Crete, Heraklion, Greece.
V GeorgouliasLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
J SouglakosLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
University of Crete · GREuropean Organisation for Research and Treatment of Cancer · BEInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differences in gene expression levels between the primary tumors (PTs) and matched regional lymph nodal metastases (LNs) in patients with totally excised non-small cell lung cancer (NSCLC) were explored. Microdissected formalin-fixed paraffin-embedded (FFPE) samples from (PT) and their matched infiltrated LNs, from 239 patients [183 (with matched PT and LNs samples)-case and 56 PT only samples-control cohorts] were analyzed for BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression by quantitative real-time polymerase-chain reaction (PCR). Moderately positive correlation between the expression of each gene in the PT and the matched LNs was observed. Concordance rates between the PT and the LNs were: BRCA1 (67.7%), ERCC1 (68.4%), PKM2 (63.4%), RAP80 (68.8%), RRM1 (70.9%), RRM2 (69%), TS (72.9%), TSP1 (69.8%), TXR1 (63.7%). Expression levels and their differences were correlated with Relapse-Free Survival (RFS) and Overall Survival (OS). High BRCA1 PT in patients with squamous histology was associated with increased OS (p = 0.036). High TSP1 PT levels were shown to be the only independent prognostic factor for OS and RFS (p = 0.023 and p = 0.007). PKM2 low levels in both PT and matched LNs were associated with better OS irrespective of the underlying histology (p = 0.031). RRM1 discordant levels between PT and matched LNs were associated with worse OS in squamous tumors (p = 0.019) compared to patients with both low expression in PT and LN.TXR1 high levels in both PT and matched LNs were associated with better OS in patients with squamous tumors (p = 0.007).These findings indicate that there is different gene expression between PT and matched LNs which may affect the outcome in early NSCLC and therefore PT's molecular biology should not be the sole determinant for prognostication.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleGene ExpressionHumansLung NeoplasmsLymphatic MetastasisLymph NodesMaleMiddle AgedNeoplasm ProteinsPrognosisRNA, MessengerBiomarkers, TumorNeoplasm ProteinsRNA, Messenger

Identifiers

PMID29472587
OpenAlexW2792110956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.